NYMC Faculty Publications

Revolutionizing Diabetes Care: Unveiling Tirzepatide's Potential in Glycemic Control and Beyond

Author Type(s)

Faculty

DOI

10.1080/17512433.2024.2310070

Journal Title

Expert Review of Clinical Pharmacology

First Page

235

Last Page

246

Document Type

Review Article

Publication Date

3-2024

Department

Medicine

Keywords

Pregnancy, Humans, Glycemic Control, Blood Glucose, Diabetes Mellitus, Gastric Inhibitory Polypeptide, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor, Hypoglycemic Agents, Glucagon-Like Peptide-2 Receptor, Tirzepatide

Disciplines

Medicine and Health Sciences

Abstract

INTRODUCTION: Diabetes is a global public health challenge with rising prevalence. This review explores current diabetes understanding, diagnostic and management guidelines, economic impact, and lifestyle modifications as the primary approach.

AREAS COVERED: Focusing on pharmacological interventions, we discuss the roles of GLP-1 agonists and GLP/GIP agonists in diabetes management and cardiovascular risk reduction. Tirzepatide, a novel medication, is highlighted for its unique mechanism of action. Clinical trials demonstrate its effectiveness in glucose control, weight reduction, and its potential impact on diabetes, obesity, NASH, and cardiovascular risks.

EXPERT OPINION: Tirzepatide shows promise in diabetes treatment, offering glucose control and weight loss. It also holds potential for addressing comorbidities. However, cautious use is vital due to potential adverse effects and contraindications, including hypersensitivity reactions, pregnancy, and breastfeeding precautions. This review underscores tirzepatide as a valuable addition to diabetes therapies, with evolving prospects for enhanced patient outcomes as research advances.

Link to Full Text

Share

COinS